Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds outpace prior hauls.

The FDA and NIH recently announced plans to phase out animal testing requirements for some therapies. While organoid and AI ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

Lantern Pharma's Q1 2025 earnings reveal clinical progress, AI commercialization plans, and financial discipline.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

AI adoption in pharma can be slow, but failing to scale these new tools across your organization is a missed opportunity.

The unintentional theme of today’s issue is the struggle for control over how we implement AI in the U.S. On one side, where ...

FDA seeking 'aggressive' adoption of AI . The FDA announced an "aggressive timeline" to deploy artificial intelligence ...

The Food and Drug Administration is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, ...

Experts have cautioned against adopting the technology too quickly for clinical purposes. The first meeting of FDA’s Digital ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement generative artificial intelligence ...